Exxon Mobil has steadied this week — up roughly 1.4% to $139.73 — but the month-long slide has left it trading at a 22% discount to the Street's mean target, and the macro headwinds that drove the sell-off have not gone away.
The tentative recovery needs context. Last week's note documented a $137.81 close after a 6% weekly drop. This week's bounce is real but modest. The stock remains down 10% over the past month. More to the point, the peer group bounced harder on Tuesday: EOG gained 2.2% on the day, OVV jumped 4.2%, and APA recovered 3.5%, all outpacing XOM's 0.9% daily move. The integrated major is no longer the worst performer week-over-week — OXY fell 8% and CVX dropped 6.5% — but XOM's relative sluggishness on the bounce is worth noting. Energy broadly is recovering from crude's recent consolidation, and XOM is participating less than the pure-play names.
Positioning in the lending market is entirely benign and does not add to the bearish story. Short interest has been unwinding, not building — it has fallen roughly 7% over the past week to just under 1% of the free float, down from a local peak near 1.2% in mid-June. Borrow availability is essentially infinite, with over 2.6 billion shares available in the lending pool against a short position of 42 million. Cost to borrow has ticked up 46% on the week to 0.49%, but that is a move from near-zero to still near-zero, and the absolute level remains among the lowest in the market. Options positioning has turned less defensive than usual — the put/call ratio at 0.68 is running below its 20-day average of 0.74, about 1.2 standard deviations light on the put side. There is no squeeze pressure here, and there is no options-market alarm signal. The short-side story is one of retreat, not conviction.
The Street's view is constructive but increasingly frustrated by the gap between target and price. The consensus is Buy, with a mean target of $170.24 — implying 22% upside from current levels. The most significant recent action was B of A Securities upgrading to Buy last week with a $154 target, the first concrete upgrade in the recent period, though it has not arrested the slide. Barclays and Mizuho both raised targets in late May, to $182 and $175 respectively, while maintaining positive ratings. Bernstein trimmed its target from $195 to $182 in mid-May but kept Outperform. The direction of travel from the sell side remains broadly positive, but the spread between where analysts have targets and where the stock is trading is now wide enough to raise the obvious question: is the Street right, or is it lagging a deteriorating oil macro? The bull case rests on Permian and Guyana (Liza) growth plus a higher oil price scenario. The bear case centres on downstream and chemicals weakness, Middle East outage risk, and an EPS revision cycle that has been negative for 2026. On valuation, the P/E has compressed to roughly 12.5x and the EV/EBITDA multiple is near 7x — neither stretched, but the PE has shed almost 2 full turns over the past month, reflecting the price decline rather than any earnings upgrade.
Factor scores show an interesting split. The short score ranks in the 75th percentile and utilization ranks similarly — both read as "shorts are cautious" relative to the wider universe. The dividend score sits at 66, reflecting XOM's well-established income credentials, though the dividend history in the data runs stale to 2022 and recent dividend information is not available to cite precisely. EPS surprise sits at 57 — broadly in line with expectations historically, neither a consistent beat nor a miss machine.
Q2 earnings land on July 31, roughly five weeks out. The most recent quarterly print produced a modest day-one decline of under 0.5%, followed by a 6.3% five-day loss — suggesting the market's reaction to recent results has been to sell into any initial stability rather than reward the numbers. With the stock already down 10% in a month, the set-up into that print is less about the multiple and more about whether downstream and chemicals guidance for the second half can stabilise the earnings revision cycle.
See the live data behind this article on ORTEX.
Open XOM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
